BioLineRx Ltd (BLRX)

[midastouch017]

Thank you, Mali. In closing, as is our custom, I would like to take a few moments to summarize our key upcoming milestones. First, initial results from Part 2 of the Phase 1/2a trial of AGI-134 in solid tumors in the second half of this year, also a pre-NDA meeting with the FDA for stem cell mobilization in the second half of this year, and then an NDA submission for stem cell mobilization in the first half of 2022.

Of course, this list does not take into account any potential partnering or strategic transactions, and while we cannot guarantee that a transaction will ultimately come to fruition, discussions with multiple parties are ongoing.